Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2011

View Archived Issues

Safety data presented from clinical evaluation of BIBF-1120 in hepatocellular carcinoma

New qRT-PCR-based microRNA profiling technique serves as diagnostic tool in CTCL

Ardea Biosciences provides update on lesinurad development

Results presented from several clinical studies assessing zonisamide in partial epilepsy

Bristol-Myers Squibb describes new chemokine CCR2 receptor antagonists

Boehringer Ingelheim Pharma patents novel therapies for HIV

New nitric oxide donors claimed for diabetes-associated neuropathic pain

Phase I/II data presented on DAC-060 in nonmelanoma skin cancer

Novartis develops novel cyclin-dependent kinase inhibitors

New glycoprotein-Ig fusion proteins generated to elicit immunity against HCV

BioLineRx signs agreement with Tel Aviv University for BL-7050

Pharnext gathers funds for further development of Pleodrug for Charcot-Marie-Tooth disease

Novel recombinant proteins catalyze tRNA aminoacylation

Trophos completes enrollment in pivotal study of olesoxime

Pluristem's PLX cells show promise in preclinical studies

Repros Therapeutics presents phase II data on low-dose Proellex

FDA clears DelMar Pharmaceuticals' IND for phase I/II VAL-083 trial

Bristol-Myers Squibb acquires Amira Pharmaceuticals

FDA committee issues recommendation on rivaroxaban to prevent stroke and systemic embolism in AF

NeurogesX submits sNDA for Qutenza to FDA

Alchemia opens recruitment in phase II HA-irinotecan trial

Spherix combination treatment reduces VLDL and LDL in preclinical study

ME-143 enters clinical development

HUYA Bioscience partners with Chinese university

Enterologics completes acquisition of BioBalance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...